Documents

Zero-tolerance code of conduct. Counteracting gender-based violence, including sexual harassment, in the EU research and innovation system (2024)

Published on
| 2 years ago
Programmes
  • Enhancing EU R&I

This document was developed by the ERA Forum Sub-group ‘Inclusive Gender Equality in the ERA’, in close cooperation with the European Commission. It aims to address incidents of gender-based violence in research and higher education environments by setting out a common approach, definitions, and a list of principles to guide Member States and other stakeholders and individuals, to create a European Research and Innovation environment free from all forms of gender-based violence, based on the values of gender equality and inclusiveness, respect, dignity and safety. (from the report’s back cover)

myOverview

Sign up for personalised information

Stay informed about Horizon Europe, Digital Europe & EDF, filtered on what matters to you.

  • News in your domains
  • Event announcements
  • A personal dashboard
Sign up now

Only for stakeholders located in Flanders

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.